A pharmacogenetic study implicates SLC9A9 in multiple sclerosis disease activity

This study identifies and validates the role of rs9828519, an intronic variant in SLC9A9, in IFNβ‐treated subjects, demonstrating a successful pharmacogenetic screen in MS. Functional characterization suggests that SLC9A9, an Na+‐H+ exchanger found in endosomes, appears to influence the differentiation of T cells to a pro‐inflammatory fate and may have a broader role in MS disease activity, outside of IFNβ‐treatment. This article is protected by copyright. All rights reserved.

Source: Annals of Neurology - April 25, 2015 Category: Neurology Authors: Federica Esposito, Melissa Sorosina, Linda Ottoboni, Elaine T. Lim, Joseph M. Replogle, Towfique Raj, Paola Brambilla, Giuseppe Liberatore, Clara Guaschino, Marzia Romeo, Thomas Pertel, James M. Stankiewicz, Vittorio Martinelli, Mariaemma Rodegher, Howard Tags: Research Article Source Type: research